Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Arm, Multicentre, Proof of Concept, Phase 2 Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After Allogeneic Hematopoietic Stem Cell Transplantation

NCT04731298 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.

NCT NCT04731298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04731298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Arm, Multicentre, Proof of Concept, Phase 2 Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Swedish Orphan Biovitrum
Phase
Phase 2
Overall status
Terminated
Start date
May 25, 2021
Completion date
April 21, 2022
Enrollment
2 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

graft failure